WO2008125116A3 - Inhibition de l'u-par - Google Patents
Inhibition de l'u-par Download PDFInfo
- Publication number
- WO2008125116A3 WO2008125116A3 PCT/DK2008/050075 DK2008050075W WO2008125116A3 WO 2008125116 A3 WO2008125116 A3 WO 2008125116A3 DK 2008050075 W DK2008050075 W DK 2008050075W WO 2008125116 A3 WO2008125116 A3 WO 2008125116A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aptamers
- present
- prevention
- proteolytic activity
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des aptamères capables de se lier à une forme de la protéine activatrice du plasminogène de type urokinase, u-PA, se liant à un récepteur. D'autre part, la présente invention concerne l'utilisation des aptamères pour la prévention de l'activité protéolytique favorisée par l'u-PA à la surface cellulaire afin de préparer une composition destinée à prévenir, ou à contrer, l'activité protéolytique à la surface d'une cellule. Les aptamères de la présente invention peuvent de plus être utilisés comme agents d'imagerie ou utilisés pour le traitement ou la prévention du cancer et/ou de la dissémination métastatique. La présente invention concerne également des compositions pharmaceutiques et des kits de diagnostic comprenant des aptamères.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200700506 | 2007-03-31 | ||
DKPA200700506 | 2007-03-31 | ||
DKPA200701559 | 2007-11-01 | ||
DKPA200701559 | 2007-11-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008125116A2 WO2008125116A2 (fr) | 2008-10-23 |
WO2008125116A3 true WO2008125116A3 (fr) | 2009-03-12 |
Family
ID=39864405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2008/050075 WO2008125116A2 (fr) | 2007-03-31 | 2008-03-28 | Inhibition de l'u-par |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008125116A2 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011341018A1 (en) * | 2010-12-10 | 2013-07-25 | Merck Patent Gmbh | Aptamer labeled with F-19 nucleus for targeted molecular imaging by MRI |
HUE048574T2 (hu) | 2012-07-12 | 2020-08-28 | Hangzhou Dac Biotech Co Ltd | Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
CN114262344A (zh) | 2014-02-28 | 2022-04-01 | 杭州多禧生物科技有限公司 | 带电荷链接体及其在共轭反应上的应用 |
CA2991973C (fr) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Lieurs de pontage pour la conjugaison d'une molecule de liaison cellulaire |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
CN106497919A (zh) | 2016-11-02 | 2017-03-15 | 四川大学 | 一种核酸适配体as1411修饰的dna四面体及其制备方法 |
KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
WO2019165105A1 (fr) * | 2018-02-26 | 2019-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Ligands du récepteur d'urokinase et leur utilisation dans le traitement, le dépistage et l'imagerie du cancer |
AU2019452577B2 (en) | 2019-06-29 | 2023-08-24 | Hangzhou Dac Biotech Co., Ltd. | Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor |
CN111453729B (zh) * | 2019-08-26 | 2021-06-18 | 山东大学 | 一种超声波辅助制备超级活性炭的方法及其应用 |
EP4194555A1 (fr) * | 2021-12-09 | 2023-06-14 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Aptamères d'adn inhibant la liaison d'activateur du plasminogène de type urokinase (upa) avec un récepteur d'activateur de plasminogène de type urokinase (upar) et l'activité upa |
-
2008
- 2008-03-28 WO PCT/DK2008/050075 patent/WO2008125116A2/fr active Application Filing
Non-Patent Citations (7)
Title |
---|
HAMULA C.L.A. ET AL.: "Selection and analytical applications of Aptamers", TRENDS IN ANALYTICAL CHEMISTRY, vol. 25, no. 7, 2006, pages 681 - 691, XP002509244 * |
JAYASENA S.D.: "Aptamers: an emerging class of molecules that rival antibodies in diagnostics", CLINICAL CHEMISTRY, vol. 45, no. 9, 1999, pages 1628 - 1650, XP002509245 * |
SCHMITT M. ET AL.: "The Urokinase Plasminogen Activator system as a novel target for tumour therapy", FIBRINOLYSIS & PROTEOLYSIS, vol. 14, no. 2/3, 2000, pages 114 - 132, XP002509198 * |
SCHWEINITZ A. ET AL.: "Design of novel and selective inhibitors of urokinase-type Plasminogen Activator with improved pharmakokinetic properties for use as antimetastatic agents", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 32, 6 August 2004 (2004-08-06), pages 33613 - 33622, XP002509197 * |
SKRYPINA N.A. ET AL.: "In vitro selection of single-stranded DNA aptamers that bind human pro-urokinase", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 23, no. 6-7, October 2004 (2004-10-01), pages 891 - 893, XP008100024 * |
ULRICH H.: "DNA and RNA Aptamers as modulators of protein function", MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, BUSSUM, NL, vol. 1, no. 2, 1 March 2005 (2005-03-01), pages 199 - 208, XP001248936, ISSN: 1573-4064 * |
ULRICH H.: "RNA Aptamers: from basic science towards therapy", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 173, 2006, pages 305 - 326, XP001249105 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008125116A2 (fr) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008125116A3 (fr) | Inhibition de l'u-par | |
EP1859793A4 (fr) | Nouvelle utilisation combinee d'un compose de sulfonamide | |
TN2009000137A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
CL2007002017A1 (es) | Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple. | |
WO2008028965A3 (fr) | Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications | |
WO2007087068A3 (fr) | Inhibiteurs de tyrosine kinase et leurs utilisations | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
CL2011001863A1 (es) | Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07). | |
BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
WO2006091395A3 (fr) | Inhibiteurs d'activite d'akt | |
IL228952B (en) | Use of preparations containing iron citrate to prepare drugs to reduce serum phosphate levels | |
WO2006135627A3 (fr) | Inhibiteurs de l'activite akt | |
BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
WO2009031106A3 (fr) | Utilisation d'une combinaison d'hespéridine et d'un micro-organisme pour influer sur la fonction de barrière de la peau | |
WO2008030883A3 (fr) | Traitement du cancer | |
WO2006096439A3 (fr) | Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees | |
WO2009114725A3 (fr) | Mobilisation de cellules souches hématopoïétiques | |
WO2006110638A3 (fr) | Inhibiteur de l'activite akt | |
WO2006113483A3 (fr) | Methodes et compositions pour le traitement ou la prevention du cancer | |
WO2007016338A3 (fr) | Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer | |
CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
WO2005099749A3 (fr) | Methodes pour controler une angiogenese et une proliferation cellulaire | |
WO2008042480A3 (fr) | Inhibiteurs époxyde de cystéine protéases | |
CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
WO2007010394A3 (fr) | Inhibition du potentiel tumorigene de cellules souches tumorales par lif (facteur inhibiteur de la leucemie) et bmps (proteines morphogenetiques osseuses) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08715629 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08715629 Country of ref document: EP Kind code of ref document: A2 |